Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2020 · 51 positions · Total reported value $3.34B · Top-10 concentration 62.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2020 13F filing, Casdin Capital disclosed 51 equity positions with a combined reported value of $3.34B. The filing implies a focused portfolio: its ten largest positions account for 62.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2020 were NVTAQ ($514.18M), BLFS ($296.79M), FATE ($277.34M). By sector, the heaviest allocations are Health Care 56.0%, Industrials 7.7%. Versus the prior quarter, allocation shifted toward Industrials (+3.6pp), Health Care (+2.2pp) and away from Other (-5.8pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q4 2020 were EXAS ($196.77M), BEAM ($37.55M), FDMT ($32.35M).

Of the 3 positions fully exited versus the prior quarter, the largest were MYOK ($118.61M), ILMN ($9.27M), ORTX ($7.69M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2020)

  • EXAS EXACT SCIENCES CORP · $196.77M
  • BEAM BEAM THERAPEUTICS INC · $37.55M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · $32.35M
  • MASS 908 DEVICES INC · $23.15M
  • KRON KRONOS BIO INC · $17.43M
  • SNDX SYNDAX PHARMACEUTICALS INC · $10.01M
  • SEER SEER INC · $8.42M
  • ABCL ABCELLERA BIOLOGICS INC · $8.05M

Fully Exited (vs previous quarter)

  • MYOK MYOKARDIA INC · prev qtr: $118.61M
  • ILMN ILLUMINA INC · prev qtr: $9.27M · history
  • ORTX ORCHARD THERAPEUTICS PLC · prev qtr: $7.69M
  • LEGN LEGEND BIOTECH CORP SPONSORED ADS · prev qtr: $4.31M
  • DCPH DECIPHERA PHARMACEUTICALS IN · prev qtr: $3.33M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 56.0%
Other 36.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.30M $514.18M 15.39%
15.39%
Add
2 7.44M $296.79M 8.88%
8.88%
Add
3 3.05M $277.34M 8.30%
8.30%
Hold
4 1.49M $196.77M 5.89%
5.89%
New
5 1.55M $173.83M 5.20%
5.20%
Hold
6 3.81M $158.30M 4.74%
4.74%
Hold
7 1.00M $141.29M 4.23%
4.23%
Hold
8 5.00M $129.70M 3.88%
3.88%
Add
9 1.31M $109.73M 3.29%
3.29%
Hold
10 2.38M $102.91M 3.08%
3.08%
Add
11 780.00K $101.38M 3.04%
3.04%
Add
12 4.33M $94.52M 2.83%
2.83%
Add
13 530.00K $90.36M 2.71%
2.71%
Hold
14 1.19M $86.46M 2.59%
2.59%
Hold
15 1.63M $64.71M 1.94%
1.94%
Hold
16 1.78M $51.41M 1.54%
1.54%
Add
17 1.61M $45.68M 1.37%
1.37%
Hold
18 1.37M $44.44M 1.33%
1.33%
Reduce
19 1.92M $44.40M 1.33%
1.33%
Hold
20 713.12K $42.17M 1.26%
1.26%
Hold
21 266.43K $40.79M 1.22%
1.22%
Hold
22 915.00K $39.59M 1.19%
1.19%
Hold
23 3.65M $39.57M 1.18%
1.18%
Add
24 150.00K $38.76M 1.16%
1.16%
Hold
25 460.00K $37.55M 1.12%
1.12%
New
26 780.55K $32.35M 0.97%
0.97%
New
27 3.35M $26.23M 0.79%
0.79%
Hold
28 190.00K $25.71M 0.77%
0.77%
Hold
29 550.00K $25.52M 0.76%
0.76%
Add
30 1.65M $24.96M 0.75%
0.75%
Hold
31 945.00K $23.85M 0.71%
0.71%
Hold
32 406.50K $23.15M 0.69%
0.69%
New
33 820.44K $21.77M 0.65%
0.65%
Hold
34 601.51K $20.36M 0.61%
0.61%
Add
35 200.00K $17.88M 0.54%
0.54%
Hold
36 583.44K $17.43M 0.52%
0.52%
New
37 1.08M $16.85M 0.51%
0.51%
Hold
38 1.24M $14.53M 0.43%
0.43%
Reduce
39 2.00M $12.35M 0.37%
0.37%
Reduce
40 450.00K $10.01M 0.30%
0.30%
New
41 289.39K $9.28M 0.28%
0.28%
Hold
42 75.00K $9.14M 0.27%
0.27%
Hold
43 150.00K $8.42M 0.25%
0.25%
New
44 200.00K $8.05M 0.24%
0.24%
New
45 370.00K $7.77M 0.23%
0.23%
Hold
46 120.00K $7.43M 0.22%
0.22%
Hold
47 216.22K $4.38M 0.13%
0.13%
New
48 6.25M $4.31M 0.13%
0.13%
Hold
49 76.69K $2.48M 0.07%
0.07%
New
50 50.00K $2.17M 0.07%
0.07%
Reduce

FAQ

What did Casdin Capital buy in 2020-Q4?

In its 2020-Q4 13F filing, Casdin Capital reported 51 equity positions worth $3.34B in aggregate; its largest disclosed positions were NVTAQ ($514.18M), BLFS ($296.79M), FATE ($277.34M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $3.34B of long equity holdings across 51 positions as of 2020-Q4. Top-10 holdings account for 62.9% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →